Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action.
about
Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptorsPharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonistPharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors.From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology.Practical considerations of the pharmacology of angiotensin receptor blockers.New insights in insurmountable antagonism.Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivoAnalysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonistBMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.Mepyramine, a histamine H1 receptor inverse agonist, binds preferentially to a G protein-coupled form of the receptor and sequesters G protein.Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.Analysis of the CCKB receptor antagonism of virginiamycin in guinea-pig ileum longitudinal myenteric plexus.Binding characteristics of [(3)H]-irbesartan to human recombinant angiotensin type 1 receptors.Reinforcement of arteriolar myogenic activity by endogenous ANG II: susceptibility to dietary salt.Clinical pharmacology of the angiotensin receptor antagonists.Distinctions between non-peptide angiotensin II AT1-receptor antagonists.
P2860
Q28343259-AC962E53-14C2-435F-959A-87E3FC151C2EQ28367875-0EE6E84C-E224-49BA-B8B8-CB3759C90AFDQ28378315-A3AC793B-7102-4C2D-BE5C-70570245F24DQ32021253-CC751789-546F-419F-87D4-44C302C98DA0Q32115544-850A232B-9117-409B-BB31-3F94CF6345D1Q33650699-32B44203-0B41-41F7-9F52-8FD83815419DQ34175396-F2676A50-9641-4FC2-817B-EEFAFF0AD336Q35376083-0B0FABA1-106D-41C4-B1BC-8641DEC83D3AQ41820935-15C6AE7E-1C93-4F84-AF0B-D5824A5E63B2Q41866496-CD139DF5-F07E-4CCC-87D9-FBD6E2615B4BQ42034040-92B95B05-853A-4D2C-AC15-022A71AA661AQ42181880-1BD3272F-5B3F-4820-B4D8-0C7AB1D9626DQ42462954-653B0245-84D5-4B37-878F-5E3869B044AAQ42702506-BC1D53C2-3E5B-4704-BBA4-BDA938FC7A0FQ42713927-7C476002-4B68-43B2-B9D9-5BCD11EAE774Q43968022-58C328F8-93D0-4649-8FDF-D6E304E3C2FFQ44873851-9C66A17F-0C5B-4DCB-8CD3-3C4AB20C3B95Q44882001-6D824ECC-F84F-4235-BB34-A511E80AB70FQ54793608-805B34A9-29F1-4630-8A0C-A350CEEC65B2
P2860
Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Evidence that the apparent com ...... eversible and syntopic action.
@en
Evidence that the apparent com ...... eversible and syntopic action.
@nl
type
label
Evidence that the apparent com ...... eversible and syntopic action.
@en
Evidence that the apparent com ...... eversible and syntopic action.
@nl
prefLabel
Evidence that the apparent com ...... eversible and syntopic action.
@en
Evidence that the apparent com ...... eversible and syntopic action.
@nl
P2093
P2860
P1476
Evidence that the apparent com ...... eversible and syntopic action.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1992.TB14322.X
P407
P577
1992-06-01T00:00:00Z